MXPA03003870A - Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. - Google Patents
Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.Info
- Publication number
- MXPA03003870A MXPA03003870A MXPA03003870A MXPA03003870A MXPA03003870A MX PA03003870 A MXPA03003870 A MX PA03003870A MX PA03003870 A MXPA03003870 A MX PA03003870A MX PA03003870 A MXPA03003870 A MX PA03003870A MX PA03003870 A MXPA03003870 A MX PA03003870A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- diabetic
- anticonvulsant agents
- anticonvulsant
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Se describen combinaciones de terapia que comprenden agentes antidiabeticos y derivados anticonvulsivos utiles para el tratamiento de diabetes mellitus tipo II y sindrome X.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24422500P | 2000-10-30 | 2000-10-30 | |
PCT/US2001/050840 WO2002064210A2 (en) | 2000-10-30 | 2001-10-25 | Combination therapy comprising anti-diabetic and anticonvulsant agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03003870A true MXPA03003870A (es) | 2004-08-12 |
Family
ID=22921886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03003870A MXPA03003870A (es) | 2000-10-30 | 2001-10-25 | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. |
Country Status (17)
Country | Link |
---|---|
US (2) | US6686337B2 (es) |
EP (1) | EP1333887B1 (es) |
JP (1) | JP2004518718A (es) |
AT (1) | ATE334718T1 (es) |
AU (1) | AU2002253838B2 (es) |
BR (1) | BR0115055A (es) |
CY (1) | CY1106195T1 (es) |
DE (1) | DE60121988T2 (es) |
DK (1) | DK1333887T3 (es) |
ES (1) | ES2269297T3 (es) |
MX (1) | MXPA03003870A (es) |
NZ (1) | NZ537490A (es) |
PT (1) | PT1333887E (es) |
RU (1) | RU2003112618A (es) |
TW (1) | TWI239840B (es) |
WO (1) | WO2002064210A2 (es) |
ZA (1) | ZA200304194B (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998256A (en) | 1996-11-01 | 1999-12-07 | Micron Technology, Inc. | Semiconductor processing methods of forming devices on a substrate, forming device arrays on a substrate, forming conductive lines on a substrate, and forming capacitor arrays on a substrate, and integrated circuitry |
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
JP4590158B2 (ja) * | 2001-04-04 | 2010-12-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法 |
EP2301537A1 (en) | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7375111B2 (en) | 2003-04-29 | 2008-05-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
DE60331236D1 (de) * | 2003-07-24 | 2010-03-25 | Eswaran Krishnan Iyer | Orale zusammensetzungen zur behandlung von diabetes |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2004265341A1 (en) * | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1697342A2 (en) * | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007517901A (ja) * | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102140090A (zh) | 2004-03-15 | 2011-08-03 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
CN101094689B (zh) * | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2006278575A1 (en) * | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
PT1922430T (pt) * | 2005-09-08 | 2019-04-12 | Erasteel Kloster Ab | Aço rápido fabricado por pulverometalurgia |
MY159522A (en) * | 2005-09-14 | 2017-01-13 | Takeda Pharmaceuticals Co | Administration of dipeptidyl peptidase inhibitors |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US20100029941A1 (en) * | 2006-03-28 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
WO2008027557A2 (en) * | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
KR20090088854A (ko) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 |
TW200829235A (en) | 2006-11-09 | 2008-07-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications |
KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
ES2312308T3 (es) | 2006-11-17 | 2013-03-26 | Supernus Pharmaceuticals, Inc. | Formulaciones de liberación sostenida de topiramato |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
MX2009003911A (es) * | 2006-12-04 | 2009-05-28 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion inmediata, mejoradas de topiramato. |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US11241420B2 (en) * | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20090076128A1 (en) * | 2007-09-15 | 2009-03-19 | Protia Llc | Deuterium-enriched topiramate |
CN101939022A (zh) * | 2007-11-14 | 2011-01-05 | 安米林药品公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
KR101512386B1 (ko) * | 2008-04-08 | 2015-04-17 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
EP2303025A4 (en) * | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US20100113603A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113583A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045563A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2010151565A2 (en) * | 2009-06-26 | 2010-12-29 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011008490A2 (en) * | 2009-06-29 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011009115A2 (en) * | 2009-07-17 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR101591357B1 (ko) | 2015-03-24 | 2016-02-04 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
IL103172A (en) | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
ATE224189T1 (de) * | 1996-06-28 | 2002-10-15 | Ortho Mcneil Pharm Inc | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit |
UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
EP1158973B1 (en) | 1999-02-24 | 2005-05-04 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
WO2000061140A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
CA2369093C (en) | 1999-04-08 | 2005-10-18 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
CA2686633A1 (en) | 1999-06-14 | 2000-12-21 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
-
2001
- 2001-10-25 BR BR0115055-3A patent/BR0115055A/pt not_active IP Right Cessation
- 2001-10-25 NZ NZ537490A patent/NZ537490A/en unknown
- 2001-10-25 AT AT01270165T patent/ATE334718T1/de active
- 2001-10-25 EP EP01270165A patent/EP1333887B1/en not_active Expired - Lifetime
- 2001-10-25 PT PT01270165T patent/PT1333887E/pt unknown
- 2001-10-25 US US10/042,425 patent/US6686337B2/en not_active Expired - Lifetime
- 2001-10-25 WO PCT/US2001/050840 patent/WO2002064210A2/en active IP Right Grant
- 2001-10-25 DE DE60121988T patent/DE60121988T2/de not_active Expired - Lifetime
- 2001-10-25 JP JP2002564002A patent/JP2004518718A/ja active Pending
- 2001-10-25 AU AU2002253838A patent/AU2002253838B2/en not_active Ceased
- 2001-10-25 MX MXPA03003870A patent/MXPA03003870A/es active IP Right Grant
- 2001-10-25 DK DK01270165T patent/DK1333887T3/da active
- 2001-10-25 RU RU2003112618/14A patent/RU2003112618A/ru not_active Application Discontinuation
- 2001-10-25 ES ES01270165T patent/ES2269297T3/es not_active Expired - Lifetime
- 2001-10-30 TW TW090126821A patent/TWI239840B/zh not_active IP Right Cessation
-
2003
- 2003-05-29 ZA ZA200304194A patent/ZA200304194B/en unknown
-
2004
- 2004-01-23 US US10/764,424 patent/US20040157785A1/en not_active Abandoned
-
2006
- 2006-10-12 CY CY20061101467T patent/CY1106195T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1333887B1 (en) | 2006-08-02 |
US20040157785A1 (en) | 2004-08-12 |
AU2002253838B2 (en) | 2006-11-09 |
EP1333887A2 (en) | 2003-08-13 |
NZ537490A (en) | 2006-11-30 |
US6686337B2 (en) | 2004-02-03 |
ZA200304194B (en) | 2004-08-30 |
BR0115055A (pt) | 2003-12-30 |
JP2004518718A (ja) | 2004-06-24 |
ES2269297T3 (es) | 2007-04-01 |
US20020147157A1 (en) | 2002-10-10 |
ATE334718T1 (de) | 2006-08-15 |
PT1333887E (pt) | 2006-10-31 |
TWI239840B (en) | 2005-09-21 |
WO2002064210A2 (en) | 2002-08-22 |
WO2002064210A3 (en) | 2003-03-06 |
DK1333887T3 (da) | 2006-11-13 |
CY1106195T1 (el) | 2011-06-08 |
DE60121988D1 (de) | 2006-09-14 |
RU2003112618A (ru) | 2004-09-27 |
DE60121988T2 (de) | 2007-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03003870A (es) | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. | |
MY126897A (en) | Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x | |
MY180762A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators. | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
MXPA03001001A (es) | Derivados anticonvulsionantes utiles para el tratameinto de la depresion. | |
EP1389621A4 (en) | N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF | |
AU5760900A (en) | Multiple agent diabetes therapy | |
HUP0200556A3 (en) | Medicament for treating diabetes | |
MY148432A (en) | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators. | |
EP1115422A4 (en) | USE OF NON-PEPTIDYLIC COMPOUNDS FOR THE TREATMENT OF INSULIN-RELATED CONDITIONS | |
AU2000276362A1 (en) | Composition for the treatment of diabetes | |
ZA200003236B (en) | Combination therapy for the treatment of migraine. | |
ZA9810214B (en) | 2-arylbenzo(b)thiophenes useful for the treatment of estrogen deprivation syndrome. | |
HK1051692A1 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain. | |
GB9907571D0 (en) | Compounds | |
ZA200110436B (en) | Therapeutic use of melatonin. | |
WO2002024181A3 (en) | The use of melatonin for induction of general anesthesia | |
AU2001285156A1 (en) | Combination therapy for the treatment of migraine | |
HU0001891D0 (en) | Medicament for the treatment of migraine | |
MXPA01013023A (es) | Agentes terapeuticos. | |
ZA200003235B (en) | Combination therapy for the treatment of migraine. | |
AU2001275696A1 (en) | Therapeutic agent | |
GB0212790D0 (en) | Medicament for the treatment of diabetes | |
ZA200002343B (en) | Combination therapy for the treatment of migraine. | |
GEP20074097B (en) | Use of specific dose of fondaparinux sodium for the treatment of acs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |